Itinai.com close up of doctor hands doing procedure for patie b62daafd ae78 4416 b629 6e501ccde339 1
Itinai.com close up of doctor hands doing procedure for patie b62daafd ae78 4416 b629 6e501ccde339 1

Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3-year survival update and multi-omics analysis

Atezolizumab and Bevacizumab for Mucosal Melanoma: Key Findings

Background

Atezolizumab combined with bevacizumab has shown promising results for patients with advanced mucosal melanoma. This report updates the survival rates over three years and analyzes data to find markers that predict treatment responses.

Methods

Forty-three patients received atezolizumab and bevacizumab through intravenous infusion every three weeks. Samples were analyzed using various genetic sequencing techniques to look for links between genetics and clinical outcomes.

Results

After an average follow-up of 40.3 months:

  • The median overall survival was 23.7 months.
  • The three-year survival rate was 28.7%.

Patients with upper site melanomas had better progression-free survival, higher tumor neoantigen burden, and greater genetic variations compared to those with lower site melanomas. NRAS mutations were linked to improved treatment response, with many patients showing positive effects. Certain biological indicators like inflammatory cell presence and angiogenesis could help predict treatment outcomes.

Conclusions

The three-year results affirm that the combination of atezolizumab and bevacizumab is effective for advanced mucosal melanoma. Tumors located in the upper body and the presence of NRAS mutation have shown to be good indicators of positive responses. Targeting specific biological pathways might enhance treatment results further.

Key Points

  • Three-year follow-up confirms treatment effectiveness.
  • Upper site tumors and NRAS mutations respond better to treatment.
  • Inflammatory markers and genetic pathways may help predict outcomes.

Enhancing Clinical Trials

Clinical trials are vital for developing safe treatments. DocSym’s AI platform brings together clinical standards and research, making it easy for doctors to access vital information.

Streamlining Healthcare Operations

In today’s healthcare landscape, efficiency is essential. Our mobile apps facilitate scheduling, treatment monitoring, and telemedicine, simplifying patient care management.

Improving Patient Outcomes

By implementing AI solutions, clinics can optimize their processes, reduce paperwork, and enhance patient outcomes. Discover more at aidevmd.com.

AI-Powered Health Tools

Interactive AI Tools to Help You Understand Your Health

Solutions for Smart Healthcare

Clinical Research